ASH® Live Review Pakistan 2022

Selected Highlights: 63rd ASH® Annual Meeting 2021
22-24 July 2022 | Virtual

What are you waiting for?

Join this historical event.



Dear friends and colleagues,

It is with immense pleasure that we welcome you, to the second ASH live Review Pakistan, American Society of Hematology (ASH) Licensed event in this part of the world. The scientific programme offers a selection of the latest advances in hematology and cutting-edge educational sessions with world experts. It will also provide a unique opportunity to share local data , real world experiences and challenges of developing countries. The event is organized by Armed Forces Bone Marrow Transplant Centre  National Institute of Blood and Marrow Transplant (AFBMTC /NIBMT), located in Rawalpindi, Pakistan. Established in 2001, AFBMTC/NIBMT is the only dedicated transplant centre of the country performing over 150 allogeneic transplants per year. AFBMTC/NIBMT is also the only centre of Pakistan to have a cellular therapy programme and an in house mesenchymal stem cell culture facility since 2015. Our ASH Live Review’s website will also provide you a chance to virtually explore Pakistan, one of the Forbes preferred tourist destination in 2021 and the land of nature and adventure. We are delighted to welcome our friends and participants from all over the world to the ASH Live Review Pakistan: Selected Highlights from the 2021 ASH Annual Meeting. We hope that this event will increase knowledge, skill, networking with new friends and colleagues and, last but not the least, to enjoy the Pakistani culture.


General Chairperson

Prof Dr Qamar Un Nisa Chaudhry
Professor of Clinical Haematology & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK

Programme Chairperson

Prof Dr Khurram Bilal Tariq, MD FACP
Chair, Dept of Hematology and medical Oncology
Seby B. Jones Cancer Center
Hematologist and medical oncologist
Boone, NC USA


Prof Dr Parvez Ahmed
Professor, Director Bone Marrow Transplant
Quaid-e-Azam International Hospital,
Islamabad - PK


Dr Syed Kamran Mahmood
Consultant Medical Specialist & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK


Dr Raheel Iftikhar
Consultant Clinical Hematologist & BMT Physician
AFBMTC/NIBMT, Rawalpindi -


Speakers & Panelists

Dr Abdul Manan

Abdul Manan

Speaker, Panelist

Damiano Rondelli

Speaker, Panelist

Haris Ali


Irum Khan

Speaker, Panelist

Jasmine M. Zain

Speaker, Panelist

Kamran Rashid

Speaker, Panelist

Mehdi Hamadani

Mehdi Hamadani

Speaker, Panelist

Naseema Gangat

Speaker, Panelist

Parvez Ahmed

Speaker, Panelist

Qaiser Bashir

Qaiser Bashir

Speaker, Panelist

Saad Z Usmani

Speaker, Panelist

Sairah Ahmed,

Sairah Ahmed

Speaker, Panelist

Salman Fazal

Speaker, Panelist

Shahrukh K. Hashmi

Speaker, Panelist

Syed Osman Ahmed

Syed Osman Ahmed

Speaker, Panelist

Tanya Siddiqi

Speaker, Panelist

Zeba Aziz


\\ Panelists //


Ghassan Umair Shamshad

Consultant Haematologist

Mehreen Ali Khan

Consultant Haematologist

Natasha Ali

Consultant Haematologist

Nighat Shahbaz

Consultant Haematologist

Raheel Iftikhar

Classified Medical Specialist & BMT Physician

Usman Ahmed

Consultant Hematologist

Faiza Noor

Consultant Clinical Hematologist

Syed Salman Hussain Shah

Syed Salman Hussain Shah

Patient Journey Partner



Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.



\\ Abstracts //

  • Day 1
  • Irum Khan
    Irum Khan 1700-1730

    1. Abstract # 333. Efficacy and safety of Venetoclax in combination with Gilteritinib for R/R FLT3-mutated AML in the expansion cohort of a phase 1b. Daver et al.
    2. Abstract # 693: Outcomes of TP53 mutant AML with Venetoclax and Decitabine. Kim et al.

  • Salman Fazal
    Salman Fazal 1730-1800

    1. Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Bas eline Erythropoietin Levels
    2. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

  • Vahid Afshar Kharghan
    Vahid Afshar Kharghan 1830-1900

    1. Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
    2. A Retrospective Cohort Study Evaluating the Safety and Efficacy of Peri-Partum Tranexamic Acid for Women with Inherited Bleeding Disorders

  • Shabeeha Rana
    Shabeeha Rana 1925-1955

    1. Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial
    2. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

  • Day 2
  • Mohammad Salman Faisal
    Mohammad Salman Faisal 1700-1705

    Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

  • Tanya Siddiqi
    Tanya Siddiqi 1705-1735

    1. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
    2. Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

  • Sairah Ahmed
    Sairah Ahmed 1800-1830

    1. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    2. Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

  • Jasmine Zain
    Jasmine Zain 1830-1900

    1. Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-
    2 and/or BCL-6 Gene Rearrangements or Increase Copy Number 2.Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

  • Naseema Gangat
    Naseema Gangat 1930-2000

    1. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
    2. abstract 481 long term use of ropeginterferon alpha 2b in PV 5 year results from a randomized controlled study

  • Day 3
  • Qamar un nisa Chaudhry
    Qamar un nisa Chaudhry 1700-1720

    1.A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: (FluCAB-Prime)
    2. Disease Progression and Outcomes in Patients with Telomere Biology Disorders

  • Hamza Hashmi
    Hamza Hashmi 1740-1810

    1. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
    2. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
    3. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
    4. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

  • Damiano Rondelli
    Damiano Rondelli 1840-1910

    1. Safety and efficacy of CTX001 in patients with transfusion-dependent beta-thalassemia and sickle cell disease: early results from the Climb THAL-111 and Climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells

  • Shahrukh K Hashmi
    Shahrukh K Hashmi 1930-2000

    1. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213
    2. REACH 3 trial: Ruxolitinib for cGVHD 3. Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Sponsored by




Novartis Logo


Contact Us

If you have any questions about the event or the team of lecturers, please send us a message and we will reply shortly.

Conference Secretariat:
AFBMTC/NIBMT, inside CMH Medical Complex, Rawalpindi – Pakistan
Tel: +92 51 9270076 Ext 228
Cell & WhatsApp: +92 322 5181302, +92 310 2500292

For more information and details, contact our customer service

Flag Counter